Nano-X Imaging Ltd. ( (NNOX) ) has released its Q3 earnings. Here is a breakdown of the information Nano-X Imaging Ltd. presented to its investors.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Nano-X Imaging Ltd., a medical imaging technology company, specializes in innovative imaging solutions leveraging advanced AI and proprietary digital X-ray sources. Operating in the healthcare sector, the company aims to make preventive healthcare more accessible globally.
In the third quarter of 2025, Nano-X Imaging Ltd. reported a revenue of $3.4 million, marking a slight increase from the previous year. The company also highlighted its strategic acquisition of Vaso Healthcare IT and several new commercial collaborations aimed at accelerating the global commercialization of its Nanox.ARC and AI solutions.
Key financial metrics for the quarter include a net loss of $13.7 million, slightly higher than the previous year’s $13.6 million. The company’s teleradiology services contributed significantly to its revenue, generating $3.1 million with improved gross profit margins. However, the company faced challenges with its imaging systems and AI solutions, both of which reported gross losses.
Despite the financial losses, Nano-X made significant strides in its strategic growth pillars, focusing on technology advancement, market expansion, and AI infrastructure development. The company secured partnerships in Europe and added new clinical trial sites in Los Angeles and Paris, enhancing its market presence.
Looking forward, Nano-X is optimistic about its growth trajectory, aiming to deploy over 100 units globally by the end of 2025. The company anticipates reaching $35 million in revenue for the year 2026, reflecting its commitment to expanding its market reach and enhancing its technological offerings.